Trials / NCT04315025
Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Cell therapy
- Sponsor
- PT. Prodia Stem Cell Indonesia
- Treatment
- Umbilical Cord Mesenchymal Stem Cell (UC-MSC); Conditioned Medium (CM)
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Started
- 2018-10-07
- Main results expected
- 2019-06-20
- Results posted
- Not yet
- Record last updated
- 2020-06-04
What the study is testing
The study will perform UC-MSCs and CM transplantation. The first group will be injected by UCMSC+NaCl. the 2nd group will be injected by UC-MSC+CM. the 3rd group will be injected by CM. Each group consists of 6 subjects. all groups will be transplanted via peribulbar route. the dosage of UC-MSC is 1 million cells for each subject. All groups will be observed until 6 months.
Where it runs
Indonesia (2)
- Jakarta Eye Center Hospital, Jakarta, DKI Jakarta
- Sardjito Hospital, Yogyakarta, Special Region